The Orexin Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the Orexin Receptor Type 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Orexin Receptor Type 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Respiratory, Toxicology, and Gastrointestinal which include the indications Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Opioid Induced Side Effects, and Reflux Esophagitis (Gastroesophageal Reflux Disease). It also reviews key players involved in Orexin Receptor Type 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Orexin Receptor Type 2 pipeline targets constitutes close to 24 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 5, 3, 4, 3, and 6 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Orexin Receptor Type 2 overview
Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
For a complete picture of Orexin Receptor Type 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
